NCT01364844View on ClinicalTrials.gov

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Solid TumorColorectal CancerEndometrial Cancer
Interventions
DRUG

DS-7423

oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily

Trial Locations (3)

10065

Memorial Sloan-Kettering Cancer Center, New York

37203

Sarah Cannon Research Institute, Nashville

48201

Karmanos Cancer Institute, Detroit

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT01364844 - Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors | Biotech Hunter | Biotech Hunter